FDA-cleared profile

VisAble.IO

Techsomed · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: VisAble.IO is CT and MR image-processing software for liver-ablation procedures. It imports images from CT and MR scanners and facility PACS systems, assists physicians with ablation-target identification and virtual ablation-needle placement, and assists confirmation of ablation zones.

Clinical role
Patient-specific image visualization, segmentation, measurement, modeling, templating, or treatment planning support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Liver, hepatic and portal veins, ablation targets, and ablation zones
Key limitation
Keep in mind: The FDA indication states that VisAble.IO is not intended for diagnosis and does not predict ablation volumes or ablation success. Planning and treatment-confirmation outputs require physician review and do not replace procedural judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: VisAble.IO is CT and MR image-processing software for liver-ablation procedures. It imports images from CT and MR scanners and facility PACS systems, assists physicians with ablation-target identification and virtual ablation-needle placement, and assists confirmation of ablation zones.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Liver, hepatic and portal veins, ablation targets, and ablation zones Input: Supported patient images, DICOM metadata, source-image geometry, and user-selected planning inputs.
  • Who uses it?Intended users: Qualified surgeons, radiologists, dentists, radiation professionals, and other trained users for the labeled planning workflow.
  • What does the software produce?Output: Segmentations, models, measurements, templates, needle or implant plans, or planning views for review and approval.
  • What is its most important limitation?Key limitation: The FDA indication states that VisAble.IO is not intended for diagnosis and does not predict ablation volumes or ablation success. Planning and treatment-confirmation outputs require physician review and do not replace procedural judgment.

Clinical takeaway. Clinical role: VisAble.IO is CT and MR image-processing software for liver-ablation procedures. It imports images from CT and MR scanners and facility PACS systems, assists physicians with ablation-target identification and virtual ablation-needle placement, and assists confirmation of ablation zones.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports bench testing of segmentation post-processing, image registration, and measurement and quantification. Reported results: CT liver segmentation (N 50) Mean DICE 0.98, ablation target (59) 0.82, ablation zone (59) 0.88, liver vessels (100) 0.72; MR liver (25) 0.93, ablation target (50) 0.76; registration MCD for pre-ablation CT to post-ablation CT (46) 4.09 mm and pre-ablation MR to post-ablation CT (25) 4.72 mm. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
VisAble.IO is CT and MR image-processing software for liver-ablation procedures. It imports images from CT and MR scanners and facility PACS systems, assists physicians with ablation-target identification and virtual ablation-needle placement, and assists confirmation of ablation zones.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Patient-specific image visualization, segmentation, measurement, modeling, templating, or treatment planning support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported patient images, DICOM metadata, source-image geometry, and user-selected planning inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Segmentations, models, measurements, templates, needle or implant plans, or planning views for review and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital, outpatient, operating-room, dental, interventional, or other labeled planning environments.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified surgeons, radiologists, dentists, radiation professionals, and other trained users for the labeled planning workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA indication states that VisAble.IO is not intended for diagnosis and does not predict ablation volumes or ablation success. Planning and treatment-confirmation outputs require physician review and do not replace procedural judgment.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports bench testing of segmentation post-processing, image registration, and measurement and quantification. Reported results: CT liver segmentation (N 50) Mean DICE 0.98, ablation target (59) 0.82, ablation zone (59) 0.88, liver vessels (100) 0.72; MR liver (25) 0.93, ablation target (50) 0.76; registration MCD for pre-ablation CT to post-ablation CT (46) 4.09 mm and pre-ablation MR to post-ablation CT (25) 4.72 mm. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance testing (Bench) was performed on the following features, to ensure that performance and accuracy was as expected: • Segmentation post-processing Testing • Image Registration Testing • Measurement and Quantification Testing" … "CT Processing Liver 50 M: 52% 60.6 US: 32 GE Medical Mean DICE =0.92 Mean DICE =0.98 Segmentation F: 48% OUS: 18 Systems, Siemens Ablation Target 59 M: 54% 60.0 US: 30 GE Medical Mean DICE = 0.70 Mean DICE = 0.82". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports bench testing of segmentation post-processing, image registration, and measurement and quantification. Reported results: CT liver segmentation (N 50) Mean DICE 0.98, ablation target (59) 0.82, ablation zone (59) 0.88, liver vessels (100) 0.72; MR liver (25) 0.93, ablation target (50) 0.76; registration MCD for pre-ablation CT to post-ablation CT (46) 4.09 mm and pre-ablation MR to post-ablation CT (25) 4.72 mm. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Performance testing (Bench) was performed on the following features, to ensure that performance and accuracy was as expected: • Segmentation post-processing Testing • Image Registration Testing • Measurement and Quantification Testing" … "CT Processing Liver 50 M: 52% 60.6 US: 32 GE Medical Mean DICE =0.92 Mean DICE =0.98 Segmentation F: 48% OUS: 18 Systems, Siemens Ablation Target 59 M: 54% 60.0 US: 30 GE Medical Mean DICE = 0.70 Mean DICE = 0.82". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K240773 FDA decision evidence for VisAble.IO

  • DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
  • PopulationLiver, hepatic and portal veins, ablation targets, and ablation zones
  • Scopeexact submission
  • Tested versionVisAble.IO
  • IndependenceSponsor or vendor study

K240773

The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K240773 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported patient images, DICOM metadata, source-image geometry, and user-selected planning inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K240773: VisAble.IO

  2. Routing

    Source context, not route validation: The FDA indication describes CT and MR import from scanners and facility PACS systems for planning and confirmation; validate patient identity, registration, image geometry, source selection, export, and procedure-room fallback locally.

    Scope: Exact FDA submission. The exact FDA material describes this input or interface boundary; local interoperability acceptance remains necessary.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K240773: VisAble.IO

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Segmentations, models, measurements, templates, needle or implant plans, or planning views for review and approval.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K240773: VisAble.IO

  5. Viewer/worklist/report

    Unresolved route: Segmentations, models, measurements, templates, needle or implant plans, or planning views for review and approval.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K240773: VisAble.IO

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA indication describes CT and MR import from scanners and facility PACS systems for planning and confirmation; validate patient identity, registration, image geometry, source selection, export, and procedure-room fallback locally.
  • Exact FDA submission
  • Checked 2026-09-04

The exact FDA material describes this input or interface boundary; local interoperability acceptance remains necessary.

Training
Only qualified surgeons, radiologists, dentists, radiation professionals, and other trained users for the labeled planning workflow should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication states that VisAble.IO is not intended for diagnosis and does not predict ablation volumes or ablation success. Planning and treatment-confirmation outputs require physician review and do not replace procedural judgment.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K240773 before acceptance. Later family features are not evidence for this exact submission.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA indication describes CT and MR import from scanners and facility PACS systems for planning and confirmation; validate patient identity, registration, image geometry, source selection, export, and procedure-room fallback locally. Test representative identifiers, geometry, measurements, units, routing, failure handling, and round trips locally.

exact submission · checked 2026-09-04

Deployment and security qualification

The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.

exact submission · checked 2026-09-04

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA indication states that VisAble.IO is not intended for diagnosis and does not predict ablation volumes or ablation success. Planning and treatment-confirmation outputs require physician review and do not replace procedural judgment.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication states that VisAble.IO is not intended for diagnosis and does not predict ablation volumes or ablation success. Planning and treatment-confirmation outputs require physician review and do not replace procedural judgment.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240773
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Liver, hepatic and portal veins, ablation targets, and ablation zones
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-04-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
33Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K240773: VisAble.IO

    U.S. Food and Drug Administration - Published 2024-04-15 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K240773 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260316

CMN Capillary Function with Oncology Virtual Expert

Cercare Medical A/S

Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-06-22
FDA-cleared K252947

HistoSonics® Planning Tool

HistoSonics, Inc.

Authorized purpose: HistoSonics Planning Tool is a stand-alone visualization and comparison tool for CT and MR studies used to plan histotripsy target localization, treatment volume, acoustic path, and patient position.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Liver; kidneys; lungs; ribs; and skin
Decision
2026-05-29
FDA-cleared K252261

InferCare RECIST

Beijing Infervision Healthcare Medical Technology Co., Ltd.

Authorized purpose: InferCare RECIST is a post-processing application for longitudinal medical-image display, lesion measurement, registration, tracking, segmentation, three-dimensional reconstruction, and RECIST reporting by trained professionals.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Tumors and lesions in adult patients age 21 and older
Decision
2026-03-13
FDA-cleared K254016

MI View&GO

Siemens Medical Solutions USA, Inc.

Authorized purpose: MI View&GO is a medical diagnostic application for viewing, manipulating, quantifying, analyzing, and comparing PET, nuclear-medicine, CT, and MR images across one or more time points, including labeled oncology, cardiology, neurology, organ-function, and radiotherapy-planning workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Whole body, organs, tumors, heart, brain, and oncology regions
Decision
2026-02-10

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history